SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Vaxart, Inc. (VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced participation in two upcoming global medical meetings in April.
Vaxart will present the following:
- Poster presenting potential new immune correlates of protection for influenza observed in the Phase 2 challenge study of its H1 influenza oral tablet vaccine at the upcoming International Society for Influenza and other Respiratory Virus Diseases’ (ISIRV) Immunological Assays and Correlates of Protection for Next Generation Influenza Vaccines conference, taking place from March 31-April 2, 2019 in Siena, Italy
- New scientific data supporting the importance of mucosal IgA to protect against influenza and a summary of data from the Phase 2 challenge study of its H1 influenza oral tablet vaccine at the upcoming Influenza Vaccines for the World (IVW) 2019, taking place from April 2-4, 2019 in Edinburgh, Scotland
Details of the presentations are as follows:
Immunological Assays and Correlates of Protection for Next Generation Influenza Vaccines Conference
Poster Title: Cell-Mediated Immunity Correlates of Protection in an Influenza Challenge Study following Vaccination via Oral Tablet in Humans
Date & Time: Monday, April 1, 2019 at 5:30 PM CET
Authors: Keith Gottlieb, et al.
Session: Poster Presentation
Influenza Vaccines for the World 2019
Presentation Title: Recent progress in novel, cross-reactive and universal influenza vaccines
Date & Time: Tuesday, April 2, 2019 at 3:40 PM GMT
Authors: Sean Tucker
Session: Session 5: Influenza Vaccines Developments II – Antigen Design and Characterization
Presentation Title: IgA is critical for protection against influenza following mucosal delivery
Date & Time: Wednesday, April 3, 2019 at 12:30 PM GMT
Authors: Nikita Kolhatkar
Session: Session 7: Influenza vaccines developments in mechanisms of action & correlates of protection
The Phase 2 study was completed with support from Biomedical Advanced Research and Development Authority (BARDA). Vaxart received a $13.9 million contract from BARDA in September 2015 to support the advanced development of more effective influenza vaccines to ultimately improve seasonal and pandemic influenza preparedness. The contract was increased to $15.7 million in 2017.
The project has been funded in whole or in part with federal funds from the Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority under Contract No. HHSO100201500034C.
Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant protein vaccines based on its proprietary oral vaccine platform. Vaxart’s vaccines are designed to generate broad and durable immune responses that protect against a wide range of infectious diseases and may also be useful for the treatment of chronic viral infections and cancer. Vaxart’s vaccines are administered using a convenient room temperature-stable tablet, rather than by injection. Vaxart believes that tableted vaccines are easier to distribute and administer than injectable vaccines and have the potential to significantly increase vaccination rates. Vaxart’s development programs include oral tablet vaccines that are designed to protect against norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV). For more information, please visit www.vaxart.com.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, prospects, plans and objectives, results from preclinical and clinical trials, commercialization agreements and licenses, beliefs and expectations of management are forward-looking statements. These forward-looking statements may be accompanied by such words as “believe,” “could,” “potential,” “will” and other words and terms of similar meaning. Examples of such statements include, but are not limited to, statements relating to the Vaxart’s ability to develop and commercialize its product candidates and clinical results and trial data; and Vaxart’s expectations with respect to the advantages it believes its oral vaccine platform can offer over injectable alternatives, particularly for mucosal pathogens such as norovirus, flu and RSV. Vaxart may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various factors could cause actual results or events to differ materially from these forward-looking statements, including Vaxart’s ability to raise sufficient capital to fund the continued development of its product candidates and complete its planned studies and trials, that Vaxart’s product candidates may not be approved by the FDA or non-U.S. regulatory authorities; that, even if approved by the FDA or non-U.S. regulatory authorities, Vaxart’s product candidates may not achieve broad market acceptance; that Vaxart may experience manufacturing issues and delays; and other risks described in the “Risk Factors” sections of Vaxart’s Quarterly and Annual Reports filed with the SEC. Vaxart does not assume any obligation to update any forward-looking statements, except as required by law.